Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.42 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.42 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.42 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.42 |
| ▸ | P2RY10 | O00398 | 7/20 | 0.42 |
| ▸ | GPR34 | Q9UPC5 | 4/20 | 0.42 |
| ▸ | GPR174 | Q9BXC1 | 3/20 | 0.42 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.39 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28884046 | 1.00 | NOS1 (0.44) | NOS1NOS3NOS2GRIK1GRIA4 | |
| SCHEMBL2507427 | 0.83 | P2RY10 (0.50) | NOS1NOS3NOS2P2RY10GPR34 | |
| SCHEMBL27139244 | 0.83 | P2RY10 (0.50) | NOS1NOS3NOS2P2RY10GPR34 | |
| SCHEMBL27872416 | 0.83 | NAAA (0.38) | NOS1NOS3NOS2P2RY10GPR34 | |
| SCHEMBL21973559 | 0.82 | SLC1A1 (0.44) | NOS1NOS3NOS2GRIK1GRIA4 | |
| SCHEMBL4893529 | 0.80 | SLC1A5 (0.43) | NOS1NOS3NOS2GRIK1GRIA4 | |
| SCHEMBL3502798 | 0.80 | SLC1A5 (0.43) | NOS1NOS3NOS2GRIK1GRIA4 | |
| SCHEMBL4893526 | 0.80 | SLC1A5 (0.43) | NOS1NOS3NOS2GRIK1GRIA4 | |
| SCHEMBL352049 | 0.80 | SLC1A5 (0.43) | NOS1NOS3NOS2GRIK1GRIA4 | |
| SCHEMBL6668936 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3562950-B1 | PROCESS FOR THE SYNTHESIS OF FUNCTIONALIZED CYCLIC DITHIOCARBAMATES | ARKEMA FRANCE (FR) | 2024-10-02 | — | — | EP | claimed |
| US-20230159967-A1 | FUNCTIONALISED POLSULPHIDE SYNTHESIS METHOD | ARKEMA FRANCE (FR) | 2023-05-25 | — | — | US | claimed |
| US-11643673-B2 | Functionalised cyclic dithiocarbamate synthesis method | ARKEMA FRANCE (FR) | 2023-05-09 | — | — | US | claimed |
| US-8518989-B2 | Prodrugs of short-chain fatty acids and treatment methods | GEORGIA HEALTH SCIENCES UNIVERSITY RESEARCH INSTITUTE, INC. (US) | 2013-08-27 | — | — | US | claimed |
| US-20110245339-A1 | PRODRUGS OF SHORT-CHAIN FATTY ACIDS AND TREATMENT METHODS | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC (US) | 2011-10-06 | — | — | US | claimed |
| US-20090123388-A1 | Prodrugs of Short-Chain Fatty Acids and Treatment Methods | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE (US) | 2009-05-14 | — | — | US | claimed |
| WO-2006076734-A2 | PRODRUGS OF SHORT-CHAIN FATTY ACIDS AND TREATMENT METHODS | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE (US) | 2006-07-20 | — | — | WO | claimed |
| EP-3562950-B1 | PROCESS FOR THE SYNTHESIS OF FUNCTIONALIZED CYCLIC DITHIOCARBAMATES | ARKEMA FRANCE (FR) | 2024-10-02 | — | — | EP | disclosed |
| US-20240002893-A1 | PROCESS FOR SYNTHESIZING FUNCTIONALIZED MERCAPTANS UNDER AN H2S PRESSURE | ARKEMA FRANCE (FR) | 2024-01-04 | — | — | US | disclosed |
| EP-4255887-A1 | METHOD FOR SYNTHESISING FUNCTIONALISED MERCAPTANS UNDER H2S PRESSURE | ARKEMA FRANCE (FR) | 2023-10-11 | — | — | EP | disclosed |
| US-20230295080-A1 | IMPROVED PROCESS FOR SYNTHESIZING FUNCTIONALIZED MERCAPTANS | ARKEMA FRANCE (FR) | 2023-09-21 | — | — | US | disclosed |
| CN-110100004-B | Synthesis of functionalized cyclic dithiocarbamic acid or ester | 阿肯马法国公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-116601143-A | For at H 2 Method for synthesizing functionalized mercaptan under S pressure | 阿科玛法国公司 | 2023-08-15 | — | — | CN | disclosed |
| US-9096642-B2 | Therapeutic compounds for immunomodulation | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-08-04 | — | — | US | disclosed |
| US-20140199334-A1 | Therapeutic Compounds for Immunomodulation | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2014-07-17 | — | — | US | disclosed |
| US-8518989-B2 | Prodrugs of short-chain fatty acids and treatment methods | GEORGIA HEALTH SCIENCES UNIVERSITY RESEARCH INSTITUTE, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20110245339-A1 | PRODRUGS OF SHORT-CHAIN FATTY ACIDS AND TREATMENT METHODS | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC (US) | 2011-10-06 | — | — | US | disclosed |
| US-20090123388-A1 | Prodrugs of Short-Chain Fatty Acids and Treatment Methods | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090123388-A1 | Prodrugs of Short-Chain Fatty Acids and Treatment Methods | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE (US) | 2009-05-14 | — | — | US | disclosed |
| WO-2006076734-A2 | PRODRUGS OF SHORT-CHAIN FATTY ACIDS AND TREATMENT METHODS | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643673-B2 | Functionalised cyclic dithiocarbamate synthesis method | TST, DTYMK, DDO | NOS1 1299/4885NOS3 1136/4885NOS2 803/4885 |
| US-20090123388-A1 | Prodrugs of Short-Chain Fatty Acids and Treatment Methods | SLC1A5, SPTSSB, SLC27A1 | NOS1 902/4885NOS3 836/4885NOS2 840/4885 |
| US-20110245339-A1 | PRODRUGS OF SHORT-CHAIN FATTY ACIDS AND TREATMENT METHODS | SLC1A5, SPTSSB, SLC27A1 | NOS1 902/4885NOS3 836/4885NOS2 840/4885 |
| US-20230159967-A1 | FUNCTIONALISED POLSULPHIDE SYNTHESIS METHOD | POLH, POLD1, POLR2H | NOS1 2674/4885NOS3 2744/4885NOS2 2232/4885 |
| US-20140199334-A1 | Therapeutic Compounds for Immunomodulation | CD274, PDCD1, PDCD1LG2 | NOS1 1848/4885NOS3 2700/4885NOS2 2179/4885 |
| US-20230295080-A1 | IMPROVED PROCESS FOR SYNTHESIZING FUNCTIONALIZED MERCAPTANS | CBR3, RTN3, OR10J3 | NOS1 547/4885NOS3 52/4885NOS2 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.